1. Home
  2. CTXR vs BIAF Comparison

CTXR vs BIAF Comparison

Compare CTXR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTXR
  • BIAF
  • Stock Information
  • Founded
  • CTXR 2007
  • BIAF 2014
  • Country
  • CTXR United States
  • BIAF United States
  • Employees
  • CTXR N/A
  • BIAF N/A
  • Industry
  • CTXR Biotechnology: Pharmaceutical Preparations
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CTXR Health Care
  • BIAF Health Care
  • Exchange
  • CTXR Nasdaq
  • BIAF Nasdaq
  • Market Cap
  • CTXR 14.6M
  • BIAF 12.2M
  • IPO Year
  • CTXR N/A
  • BIAF 2022
  • Fundamental
  • Price
  • CTXR $0.84
  • BIAF $0.49
  • Analyst Decision
  • CTXR Strong Buy
  • BIAF Hold
  • Analyst Count
  • CTXR 2
  • BIAF 1
  • Target Price
  • CTXR $54.50
  • BIAF N/A
  • AVG Volume (30 Days)
  • CTXR 679.0K
  • BIAF 28.5M
  • Earning Date
  • CTXR 05-13-2025
  • BIAF 05-14-2025
  • Dividend Yield
  • CTXR N/A
  • BIAF N/A
  • EPS Growth
  • CTXR N/A
  • BIAF N/A
  • EPS
  • CTXR N/A
  • BIAF N/A
  • Revenue
  • CTXR N/A
  • BIAF $9,362,022.00
  • Revenue This Year
  • CTXR N/A
  • BIAF N/A
  • Revenue Next Year
  • CTXR N/A
  • BIAF $19.99
  • P/E Ratio
  • CTXR N/A
  • BIAF N/A
  • Revenue Growth
  • CTXR N/A
  • BIAF 269.68
  • 52 Week Low
  • CTXR $0.81
  • BIAF $0.24
  • 52 Week High
  • CTXR $26.25
  • BIAF $3.16
  • Technical
  • Relative Strength Index (RSI)
  • CTXR 28.63
  • BIAF 48.21
  • Support Level
  • CTXR $0.81
  • BIAF $0.46
  • Resistance Level
  • CTXR $1.02
  • BIAF $0.58
  • Average True Range (ATR)
  • CTXR 0.09
  • BIAF 0.11
  • MACD
  • CTXR 0.01
  • BIAF -0.01
  • Stochastic Oscillator
  • CTXR 10.09
  • BIAF 8.65

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: